GLP-1 drugs may lower odds of developing substance use disorders
News briefs
- Reviewed by Robert H. Shmerling, MD, Senior Faculty Editor, Harvard Health Publishing; Editorial Advisory Board Member, Harvard Health Publishing
The BMJResearchers analyzed medical records from 606,434 US veterans (average age 65; 90% men), all of whom had diabetes and took either a GLP-1, such as semaglutide (Ozempic) or tirzepatide (Mounjaro), or an older diabetes drug called an SGLT-2, such as empagliflozin (Jardiance). Using the data, the researchers simulated seven clinical trials that compared the apparent effects of GLP-1s and SGLT-2 medications on people with existing substance use disorders, as well as whether the medicines could help prevent such disorders from developing.
To continue reading this article, you must log in.
Source matters. Subscribe to HarvardHealthOnline+ FREE for 30 days for unlimited access to the site – where all content is reviewed by an HMS physician or faculty expert.
With HHO+ you get these exclusive benefits:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
SPECIAL OFFER! UNLOCK EXPERT ACCESS for 30 days FREE!
Sign Me UpAlready a member? Login ».
About the Author
Maureen Salamon, Executive Editor, Harvard Women's Health Watch
About the Reviewer
Robert H. Shmerling, MD, Senior Faculty Editor, Harvard Health Publishing; Editorial Advisory Board Member, Harvard Health Publishing
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
